Rabab Mahmoud Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rabab Mahmoud Ahmed has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Amin Roshdy Soliman
Cairo University, Egypt
9 shared publications - Tarek Samy Abdelaziz
Nephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt
4 shared publications AbdelAal Mohammed
Internal Medicine and Nephrology Department, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications- Ahsan Ayaz
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
2 shared publications - Ebtesam Mohamed Fahmy
Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications Haytham Soliman
2 shared publications
Latest Publications
- Open Access
- 7 March 2026
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 18 (1)
The obesity-brain axis: a comprehensive review of neurological complications and therapeutic interventions in metabolic syndrome
Background: Obesity has emerged as a major global health issue, affecting multiple organ systems. Within the central nervous system obesity causes a series of disruptions that can significantly affect neurological function. Identifying obesity as a modifiable risk factor presents opportunities for preventive and therapeutic strategies that may significantly diminish neurological sequelae. Objective: This narrative review aims to summarize current evidence on how obesity contributes to different neurological diseases and focusing on biological mechanisms linking obesity to these conditions, outlines the characteristic clinical presentations of obesity-related neurological diseases across different age groups and potential therapeutic strategies. Methods: This narrative review integrates findings from comprehensive search of PubMed, EMBASE, and Cochrane Library to investigate how obesity and metabolic syndrome relate to a broad spectrum of neurological disorders. After screening 1,950 records, 48 studies were included supplemented by nine manually identified articles. Results: Obesity triggers a range of biological changes in the nervous system such as increased oxidative stress, persistent low‑grade inflammation, disruption of the blood–brain barrier, and impaired mitochondrial function. Together, these changes raise the risk of several neurological problems, including cognitive decline, Alzheimer’s disease, stroke, faster progression of multiple sclerosis, greater epilepsy‑related complications, transformation of episodic into chronic migraine, idiopathic intracranial hypertension, and various peripheral neuropathies. The impact of body mass index on neurological health differs across diseases and age groups with obesity in midlife representing a high risk. Lifestyle‑based strategies especially Mediterranean or ketogenic dietary patterns, regular physical activity and weight reduction show encouraging potential in reducing these neurological risks. Conclusions: Obesity is a modifiable contributor to many neurological disorders. Identifying at‑risk individuals early and adopting healthier daily habits, following tailored diets and managing weight effectively may help lessen the neurological consequences of obesity. Continued research is essential to clarify underlying mechanisms and refine treatment strategies for different patient groups.
- 7 March 2026
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 18 (1)
Open AccessThe obesity-brain axis: a comprehensive review of neurological complications and therapeutic interventions in metabolic syndrome
Background: Obesity has emerged as a major global health issue, affecting multiple organ systems. Within the central nervous system obesity causes a series of disruptions that can significantly affect neurological function. Identifying obesity as a modifiable risk factor presents opportunities for preventive and therapeutic strategies that may significantly diminish neurological sequelae. Objective: This narrative review aims to summarize current evidence on how obesity contributes to different neurological diseases and focusing on biological mechanisms linking obesity to these conditions, outlines the characteristic clinical presentations of obesity-related neurological diseases across different age groups and potential therapeutic strategies. Methods: This narrative review integrates findings from comprehensive search of PubMed, EMBASE, and Cochrane Library to investigate how obesity and metabolic syndrome relate to a broad spectrum of neurological disorders. After screening 1,950 records, 48 studies were included supplemented by nine manually identified articles. Results: Obesity triggers a range of biological changes in the nervous system such as increased oxidative stress, persistent low‑grade inflammation, disruption of the blood–brain barrier, and impaired mitochondrial function. Together, these changes raise the risk of several neurological problems, including cognitive decline, Alzheimer’s disease, stroke, faster progression of multiple sclerosis, greater epilepsy‑related complications, transformation of episodic into chronic migraine, idiopathic intracranial hypertension, and various peripheral neuropathies. The impact of body mass index on neurological health differs across diseases and age groups with obesity in midlife representing a high risk. Lifestyle‑based strategies especially Mediterranean or ketogenic dietary patterns, regular physical activity and weight reduction show encouraging potential in reducing these neurological risks. Conclusions: Obesity is a modifiable contributor to many neurological disorders. Identifying at‑risk individuals early and adopting healthier daily habits, following tailored diets and managing weight effectively may help lessen the neurological consequences of obesity. Continued research is essential to clarify underlying mechanisms and refine treatment strategies for different patient groups.
- Open Access
- 17 December 2025
- Published by Springer Nature in Journal of Health, Population and Nutrition
- Vol. 45 (1)
Counting the invisible: dietary inorganic phosphorus intake across different chronic kidney disease stages in elderly patients-a national insight
Background: There’s still a gap in research on phosphorus intake for elderly patients with chronic kidney disease. Processed and ultra-processed foods provide convenient dietary options but are significant source of harmful inorganic phosphorus. This study attempts to evaluate total phosphorus intake in elderly chronic kidney disease (CKD) patients across different stages, focusing on dietary contribution of inorganic phosphorus, stratified into tertiles, from processed and ultra-processed foods. Methods: Cross-sectional analytical study conducted using an adapted food frequency questionnaire to assess weekly consumption phosphorus patterns over the last year among 232 participants. The study investigates the frequency and types of natural high-phosphorus foods, as well as processed and ultra-processed foods commonly available in the Egyptian market. It focused on elderly chronic kidney disease patients aged over 65 years, covering various stages of chronic kidney disease, including those receiving haemodialysis, and compared their dietary intake to their caregivers and an age-matched group of individuals over 65 years without CKD. Results: Phosphorus intake among elderly CKD subgroups showed considerable inter-individuals difference, ranging 880 − 16,804 mg/week. The total median weekly phosphorus intake in CKD patients > 65 years was lower compared to caregivers, with a statistically significant difference ( p = 0.011 ) for patients aged 65–74 years. Phosphorus intake declined as CKD progressed from stage II to V. Among CKD, patients with a diploma education& who cook for themselves were significantly more likely to exceed the Dietary Reference Intake, ( p < 0.05 ).Weekly inorganic phosphorous intake showed significant proportionate with frailty score (p = 0.024). Phosphorus intake from processed food/UPF was categorized into tertiles (low (< 694.39 mg), moderate (694.39–2382.53 mg), and high (> 2382.53 mg). 41% CKD patients > 75 years were classified as low inorganic phosphorus consumers compared to 33.3% in CKD aged 65–74 years. Education level, BMI showed a significant association, p < 0.05 . Patients undergoing three dialysis sessions per week consumed more than twice the inorganic phosphorus (1,314.9 mg) compared to those receiving two sessions (552.1 mg), (p > 0.05) . CKD patients > 75 years had significantly lower consumption of nuts, legumes, and beans than caregivers (p = 0.048 ). Conclusion: Age, CKD diagnosis and stage may be additional factors in the observed variations in phosphorus-containing food intake patterns.
- 17 December 2025
- Published by Springer Nature in Journal of Health, Population and Nutrition
- Vol. 45 (1)
Open AccessCounting the invisible: dietary inorganic phosphorus intake across different chronic kidney disease stages in elderly patients-a national insight
Background: There’s still a gap in research on phosphorus intake for elderly patients with chronic kidney disease. Processed and ultra-processed foods provide convenient dietary options but are significant source of harmful inorganic phosphorus. This study attempts to evaluate total phosphorus intake in elderly chronic kidney disease (CKD) patients across different stages, focusing on dietary contribution of inorganic phosphorus, stratified into tertiles, from processed and ultra-processed foods. Methods: Cross-sectional analytical study conducted using an adapted food frequency questionnaire to assess weekly consumption phosphorus patterns over the last year among 232 participants. The study investigates the frequency and types of natural high-phosphorus foods, as well as processed and ultra-processed foods commonly available in the Egyptian market. It focused on elderly chronic kidney disease patients aged over 65 years, covering various stages of chronic kidney disease, including those receiving haemodialysis, and compared their dietary intake to their caregivers and an age-matched group of individuals over 65 years without CKD. Results: Phosphorus intake among elderly CKD subgroups showed considerable inter-individuals difference, ranging 880 − 16,804 mg/week. The total median weekly phosphorus intake in CKD patients > 65 years was lower compared to caregivers, with a statistically significant difference ( p = 0.011 ) for patients aged 65–74 years. Phosphorus intake declined as CKD progressed from stage II to V. Among CKD, patients with a diploma education& who cook for themselves were significantly more likely to exceed the Dietary Reference Intake, ( p < 0.05 ).Weekly inorganic phosphorous intake showed significant proportionate with frailty score (p = 0.024). Phosphorus intake from processed food/UPF was categorized into tertiles (low (< 694.39 mg), moderate (694.39–2382.53 mg), and high (> 2382.53 mg). 41% CKD patients > 75 years were classified as low inorganic phosphorus consumers compared to 33.3% in CKD aged 65–74 years. Education level, BMI showed a significant association, p < 0.05 . Patients undergoing three dialysis sessions per week consumed more than twice the inorganic phosphorus (1,314.9 mg) compared to those receiving two sessions (552.1 mg), (p > 0.05) . CKD patients > 75 years had significantly lower consumption of nuts, legumes, and beans than caregivers (p = 0.048 ). Conclusion: Age, CKD diagnosis and stage may be additional factors in the observed variations in phosphorus-containing food intake patterns.
- Open Access
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41446
Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism
Our study investigates the effect of vonoprazan on albuminuria in diabetic kidney disease (DKD) patients compared to lansoprazole through a randomized controlled trial. Participants were randomized to receive either lansoprazole 30 mg or vonoprazan 20 mg. Specifically, 100 patients were included for H. pylori eradication, and 40 patients for other indications. The albumin/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) were measured at baseline and three months later. Both vonoprazan and lansoprazole significantly reduced ACR from baseline levels after 3 months ( p < 0.05). However, the reduction in albuminuria was significantly greater in the vonoprazan group compared to the lansoprazole group, regardless of H. pylori diagnosis or eradication success ( p < 0.05). Treatment type was a significant predictor, with a standardized beta of 0.555. Patients receiving vonoprazan experienced a 19.2-unit increase in the percentage change of ACR compared to those receiving lansoprazole (β = 19.219, 95% CI [13.62-24.817]). Additionally, vonoprazan-treated patients showed significant improvement in eGFR after 3 months compared to baseline levels ( p < 0.05), with this improvement being superior to that observed with lansoprazole ( p < 0.05). Vonoprazan may have a direct renal effect, warranting further research to elucidate its mechanism in reducing albuminuria.
- 21 November 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41446
Open AccessVonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism
Our study investigates the effect of vonoprazan on albuminuria in diabetic kidney disease (DKD) patients compared to lansoprazole through a randomized controlled trial. Participants were randomized to receive either lansoprazole 30 mg or vonoprazan 20 mg. Specifically, 100 patients were included for H. pylori eradication, and 40 patients for other indications. The albumin/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) were measured at baseline and three months later. Both vonoprazan and lansoprazole significantly reduced ACR from baseline levels after 3 months ( p < 0.05). However, the reduction in albuminuria was significantly greater in the vonoprazan group compared to the lansoprazole group, regardless of H. pylori diagnosis or eradication success ( p < 0.05). Treatment type was a significant predictor, with a standardized beta of 0.555. Patients receiving vonoprazan experienced a 19.2-unit increase in the percentage change of ACR compared to those receiving lansoprazole (β = 19.219, 95% CI [13.62-24.817]). Additionally, vonoprazan-treated patients showed significant improvement in eGFR after 3 months compared to baseline levels ( p < 0.05), with this improvement being superior to that observed with lansoprazole ( p < 0.05). Vonoprazan may have a direct renal effect, warranting further research to elucidate its mechanism in reducing albuminuria.
- Open Access
- 6 October 2025
- Published by Springer Nature in Cardiovascular Diabetology – Endocrinology Reports
- Vol. 11 (1) , 1-18
Non-diabetic hypoglycemia: bridging gaps in diagnosis and treatment: a position statement report by the Arabic Association for the Study of Diabetes and Metabolism (AASD)
Background: Non-diabetic hypoglycemia presents a substantial diagnostic challenge due to its diverse and often nonspecific symptomatology. The resultant delay in diagnosis can lead to a myriad of misdiagnoses. This misidentification not only prolongs patient suffering but also elevates the risk of severe complications, such as permanent neurologic damage and mortality. Recognizing the clinical nuances of non-diabetic hypoglycemia is paramount for timely and accurate diagnosis, which ultimately enhances patient outcomes and safety. Main Body: A position statement has been formulated by the Arabic Association for the Study of Diabetes and Metabolism (AASD) to address the complexities of diagnosing non-diabetic hypoglycemia. This statement highlights the challenges and pitfalls, covering key areas such as the vast spectrum of non-diabetic hypoglycemia within underreported subspecialties. It aims to elucidate the critical need for heightened clinical awareness and multidisciplinary management approaches to mitigate the profound impacts on patient health. Additionally, the statement provides guidance for overcoming barriers to optimal care. The team has distilled their experience into clinical algorithms to simplify information for healthcare professionals. Conclusion: Non-diabetic hypoglycemia is a rare condition that requires a comprehensive approach, including detailed history, medication review, and physical examination. Common pitfalls in diagnosis and management should be understood to avoid unnecessary evaluation and costs while avoiding misdiagnosis of patients with treatable or serious disorders.
- 6 October 2025
- Published by Springer Nature in Cardiovascular Diabetology – Endocrinology Reports
- Vol. 11 (1) , 1-18
Open AccessNon-diabetic hypoglycemia: bridging gaps in diagnosis and treatment: a position statement report by the Arabic Association for the Study of Diabetes and Metabolism (AASD)
Background: Non-diabetic hypoglycemia presents a substantial diagnostic challenge due to its diverse and often nonspecific symptomatology. The resultant delay in diagnosis can lead to a myriad of misdiagnoses. This misidentification not only prolongs patient suffering but also elevates the risk of severe complications, such as permanent neurologic damage and mortality. Recognizing the clinical nuances of non-diabetic hypoglycemia is paramount for timely and accurate diagnosis, which ultimately enhances patient outcomes and safety. Main Body: A position statement has been formulated by the Arabic Association for the Study of Diabetes and Metabolism (AASD) to address the complexities of diagnosing non-diabetic hypoglycemia. This statement highlights the challenges and pitfalls, covering key areas such as the vast spectrum of non-diabetic hypoglycemia within underreported subspecialties. It aims to elucidate the critical need for heightened clinical awareness and multidisciplinary management approaches to mitigate the profound impacts on patient health. Additionally, the statement provides guidance for overcoming barriers to optimal care. The team has distilled their experience into clinical algorithms to simplify information for healthcare professionals. Conclusion: Non-diabetic hypoglycemia is a rare condition that requires a comprehensive approach, including detailed history, medication review, and physical examination. Common pitfalls in diagnosis and management should be understood to avoid unnecessary evaluation and costs while avoiding misdiagnosis of patients with treatable or serious disorders.
- Open Access
- 29 May 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2509784
The evolution of nephrology practice in Egypt: legacy, current challenges, and future directions—a narrative review
Egypt, home to over 114 million people, hosts a diverse and expanding nephrology landscape, anchored by leading academic institutions and tertiary care centers that provide services across the full spectrum of kidney disease-from acute kidney injury (AKI) and chronic kidney disease (CKD) to dialysis and transplantation. Some centers have earned international recognition for their scientific contributions and attract referrals from across the region. Notwithstanding the range of services offered, the Egyptian healthcare system-which includes insurance-based, commercial, and governmental models-faces significant obstacles, such as unequal access to care, a lack of adequate data infrastructure, and resource limitations. This narrative review, authored by a multidisciplinary team of Egyptian nephrology experts, provides a comprehensive overview of nephrology care in Egypt, highlighting current strengths, identifying key challenges, and offering future-oriented solutions to advance kidney health nationwide. It aims to serve as a roadmap for policymakers, stakeholders, clinicians, and researchers committed to improving nephrology care delivery in Egypt and shaping a more equitable, enhanced, and sustainable future.
- 29 May 2025
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2509784
Open AccessThe evolution of nephrology practice in Egypt: legacy, current challenges, and future directions—a narrative review
Egypt, home to over 114 million people, hosts a diverse and expanding nephrology landscape, anchored by leading academic institutions and tertiary care centers that provide services across the full spectrum of kidney disease-from acute kidney injury (AKI) and chronic kidney disease (CKD) to dialysis and transplantation. Some centers have earned international recognition for their scientific contributions and attract referrals from across the region. Notwithstanding the range of services offered, the Egyptian healthcare system-which includes insurance-based, commercial, and governmental models-faces significant obstacles, such as unequal access to care, a lack of adequate data infrastructure, and resource limitations. This narrative review, authored by a multidisciplinary team of Egyptian nephrology experts, provides a comprehensive overview of nephrology care in Egypt, highlighting current strengths, identifying key challenges, and offering future-oriented solutions to advance kidney health nationwide. It aims to serve as a roadmap for policymakers, stakeholders, clinicians, and researchers committed to improving nephrology care delivery in Egypt and shaping a more equitable, enhanced, and sustainable future.
- 18 December 2024
- Published by AMALTEA Medical Publishing House in Romanian Medical Journal
- Vol. 71 (4) , 336-342
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Background. Benign prostatic hyperplasia (BPH) has recently been linked to diabetes mellitus and insulin resistance. This study aims to explore whether the use of either sodium-glucose co-transporter-2 (SGLT-2) inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with favorable outcomes in prostate volume and symptoms. Methods. This is a before-and-after study involving 57 elderly male patients with type 2 diabetes mellitus and BPH, who were recruited and followed up for one year. Twenty-seven patients were prescribed SGLT-2 inhibitors (Dapagliflozin 10 mg), and thirty patients were prescribed DPP-4 inhibitors (Sitagliptin 100 mg). Prostate volume, International Prostate Symptom Score (IPSS), and Pittsburgh Sleep Quality Index (PSQI) were assessed in all patients. Results. The use of either SGLT-2 inhibitors or DPP-4 inhibitors was associated with a statistically significant decrease in prostate volume after one year of treatment (p = 0.04 for SGLT-2 inhibitors and p = 0.02 for DPP-4 inhibitors). Statistically significant reductions were found in both groups regarding post-voiding urine volume after one year of treatment compared to baseline levels (p = 0.014 for SGLT-2 inhibitors and p = 0.017 for DPP-4 inhibitors). At the end of the follow-up period, there was a statistically significant reduction in IPSS scores (p = 0.02 for SGLT-2 inhibitors and p = 0.03 for DPP-4 inhibitors). Similarly, the use of either DPP-4 inhibitors or SGLT-2 inhibitors was associated with a statistically significant improvement in nocturia and sleep quality (PSQI score) (p = 0.012 for SGLT-2 inhibitors and p = 0.01 for DPP-4 inhibitors). Post-hoc analysis showed that DPP-4 inhibitors were superior to SGLT-2 inhibitors in reducing prostate volume and symptoms (p < 0.05). Conclusion. Both SGLT-2 inhibitors and DPP-4 inhibitors improve prostate volume and symptoms in patients with diabetes mellitus and BPH. Notably, DPP-4 inhibitors exhibited superiority over SGLT-2 inhibitors in terms of reducing prostate volume and alleviating symptoms. Larger-scale studies are required to confirm these favorable effects.
- 18 December 2024
- Published by AMALTEA Medical Publishing House in Romanian Medical Journal
- Vol. 71 (4) , 336-342
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Background. Benign prostatic hyperplasia (BPH) has recently been linked to diabetes mellitus and insulin resistance. This study aims to explore whether the use of either sodium-glucose co-transporter-2 (SGLT-2) inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors is associated with favorable outcomes in prostate volume and symptoms. Methods. This is a before-and-after study involving 57 elderly male patients with type 2 diabetes mellitus and BPH, who were recruited and followed up for one year. Twenty-seven patients were prescribed SGLT-2 inhibitors (Dapagliflozin 10 mg), and thirty patients were prescribed DPP-4 inhibitors (Sitagliptin 100 mg). Prostate volume, International Prostate Symptom Score (IPSS), and Pittsburgh Sleep Quality Index (PSQI) were assessed in all patients. Results. The use of either SGLT-2 inhibitors or DPP-4 inhibitors was associated with a statistically significant decrease in prostate volume after one year of treatment (p = 0.04 for SGLT-2 inhibitors and p = 0.02 for DPP-4 inhibitors). Statistically significant reductions were found in both groups regarding post-voiding urine volume after one year of treatment compared to baseline levels (p = 0.014 for SGLT-2 inhibitors and p = 0.017 for DPP-4 inhibitors). At the end of the follow-up period, there was a statistically significant reduction in IPSS scores (p = 0.02 for SGLT-2 inhibitors and p = 0.03 for DPP-4 inhibitors). Similarly, the use of either DPP-4 inhibitors or SGLT-2 inhibitors was associated with a statistically significant improvement in nocturia and sleep quality (PSQI score) (p = 0.012 for SGLT-2 inhibitors and p = 0.01 for DPP-4 inhibitors). Post-hoc analysis showed that DPP-4 inhibitors were superior to SGLT-2 inhibitors in reducing prostate volume and symptoms (p < 0.05). Conclusion. Both SGLT-2 inhibitors and DPP-4 inhibitors improve prostate volume and symptoms in patients with diabetes mellitus and BPH. Notably, DPP-4 inhibitors exhibited superiority over SGLT-2 inhibitors in terms of reducing prostate volume and alleviating symptoms. Larger-scale studies are required to confirm these favorable effects.
- Open Access
- 3 September 2024
- Published by Springer Nature in Journal of Health, Population and Nutrition
- Vol. 43 (1) , 1-14
Dietary recommendations for people with diabetes in special situations: a position statement report by Arabic Association for the Study of Diabetes and metabolism (AASD)
Background: Diabetes is a significant global health concern. Regional factors play a crucial role in determining the appropriate diet for patients. Main body: The Arabic Association for the Study of Diabetes and Metabolism has developed a position statement that addresses the dietary needs of patients in the context of low income and cultural dietary habits. This statement aims to explore the most suitable diet for Middle East and North Africa (MENA) region and provide guidance for physicians to overcome barriers in optimal care. While most dietary guidelines focus on uncomplicated diabetes, it’s essential to recognize that diabetes often coexists with other common diseases in our region. Conclusion: International guidelines cannot be directly applied to the Egypt and Arab countries due to cultural and dietary differences. Our position statement shares valuable insights into managing diabetes in special situations and diverse clinical settings within this region. These recommendations are flexible, considering personal, cultural, and traditional differences.
- 3 September 2024
- Published by Springer Nature in Journal of Health, Population and Nutrition
- Vol. 43 (1) , 1-14
Open AccessDietary recommendations for people with diabetes in special situations: a position statement report by Arabic Association for the Study of Diabetes and metabolism (AASD)
Background: Diabetes is a significant global health concern. Regional factors play a crucial role in determining the appropriate diet for patients. Main body: The Arabic Association for the Study of Diabetes and Metabolism has developed a position statement that addresses the dietary needs of patients in the context of low income and cultural dietary habits. This statement aims to explore the most suitable diet for Middle East and North Africa (MENA) region and provide guidance for physicians to overcome barriers in optimal care. While most dietary guidelines focus on uncomplicated diabetes, it’s essential to recognize that diabetes often coexists with other common diseases in our region. Conclusion: International guidelines cannot be directly applied to the Egypt and Arab countries due to cultural and dietary differences. Our position statement shares valuable insights into managing diabetes in special situations and diverse clinical settings within this region. These recommendations are flexible, considering personal, cultural, and traditional differences.
- Open Access
- 13 August 2024
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 36 (1) , 1-11
Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease
Introduction: Data on sodium glucose co-transporter 2 inhibitors impact on lipids in patients with diabetes are available and only a handful of studies have explored this effect in individuals with both diabetes and renal impairment; lipid parameters were not the primary focus of those earlier studies. However, there is a significant research gap specifically addressing the influence of SGLT2 inhibitors on cholesterol fractions in patients exclusively with chronic kidney disease. This aim constitutes the central objective in this particular study. Methods: In this 3-month randomized controlled study, 30 patients with stage 3 chronic kidney disease and dyslipidemia were randomly assigned to receive either dapagliflozin 10 mg or placebo. Lipid profiles, renal function, and urinary albumin levels were assessed at baseline and after 3 months. Results: Compared to baseline, patients receiving dapagliflozin for 3 months showed significant improvements in serum creatinine (p < .001) and eGFR (p = .001). Total cholesterol and LDL-C levels decreased significantly (p = .010 and .006, respectively). While albumin-creatinine ratio also decreased, this change was not statistically significant. Additionally, HDL-C and TG not significantly increased. The control group without intervention experienced deterioration in serum creatinine and eGFR (p = .008, and .011, respectively), but no statistically significant lipid changes were observed. Furthermore, post-intervention total cholesterol moderately correlated with BMI (p = .032, R = .554), yet no predictors significantly influenced lipid levels in the multiple linear regression analysis. Conclusions: Dapagliflozin has a favorable effect on cholesterol fractions in stage 3 CKD patients without diabetes mellitus and this effect was different from that observed in patients with diabetes alone.
- 13 August 2024
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 36 (1) , 1-11
Open AccessPotential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease
Introduction: Data on sodium glucose co-transporter 2 inhibitors impact on lipids in patients with diabetes are available and only a handful of studies have explored this effect in individuals with both diabetes and renal impairment; lipid parameters were not the primary focus of those earlier studies. However, there is a significant research gap specifically addressing the influence of SGLT2 inhibitors on cholesterol fractions in patients exclusively with chronic kidney disease. This aim constitutes the central objective in this particular study. Methods: In this 3-month randomized controlled study, 30 patients with stage 3 chronic kidney disease and dyslipidemia were randomly assigned to receive either dapagliflozin 10 mg or placebo. Lipid profiles, renal function, and urinary albumin levels were assessed at baseline and after 3 months. Results: Compared to baseline, patients receiving dapagliflozin for 3 months showed significant improvements in serum creatinine (p < .001) and eGFR (p = .001). Total cholesterol and LDL-C levels decreased significantly (p = .010 and .006, respectively). While albumin-creatinine ratio also decreased, this change was not statistically significant. Additionally, HDL-C and TG not significantly increased. The control group without intervention experienced deterioration in serum creatinine and eGFR (p = .008, and .011, respectively), but no statistically significant lipid changes were observed. Furthermore, post-intervention total cholesterol moderately correlated with BMI (p = .032, R = .554), yet no predictors significantly influenced lipid levels in the multiple linear regression analysis. Conclusions: Dapagliflozin has a favorable effect on cholesterol fractions in stage 3 CKD patients without diabetes mellitus and this effect was different from that observed in patients with diabetes alone.
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3183
Black Bronchoscopy: Finding a Common Answer
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3183
Black Bronchoscopy: Finding a Common Answer
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3508
Nose Necrosis in Septic Shock: Cocaine Use With Confounding Factors
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3508
Nose Necrosis in Septic Shock: Cocaine Use With Confounding Factors